We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Affymetrix and Tessare Develop Pathogen-Detection Kit

By Biotechdaily staff writers
Posted on 12 Feb 2007
Affymetrix Inc. More...
(Santa Clara, CA, USA) announced that it has granted Tessare, Inc. (Colorado Springs, CO, USA) non-exclusive access to its microarray technology to develop and market epidemiological tests for public health and biodefense surveillance.

As part of the Powered by Affymetrix program, the TessArray kits will detect and identify hundreds of strains of natural and emergent viral and bacterial pathogens, as well as biothreat agents. The resulting information will enable scientists to understand and respond to pandemic infectious disease threats.

The TessArray kits are based on multiplexed genotypic signatures present on the Affymetrix CustomSeq Resequencing Arrays. These arrays have been designed and fabricated to detect a set of upper respiratory pathogen-specific target sequences provided by the U.S. Naval Research Laboratory. Public health officials can use the resulting information to identify the most likely agent strain(s) associated with disease outbreaks.

Tessare president and co-founder Klaus Schafer, M.D., M.P.H., said, Investigators at collection sites can determine whether detected pathogen strains warrant elevated epidemic or pandemic concerns. The TessArray kits enable a level of strain and sub-strain discrimination not possible with other array-based methodologies, as well as the ability to detect and characterize novel nucleotide changes in the pathogen genome sequence at the same time.

With the recent emergence of new infectious diseases such as avian influenza, it is important for global health organizations to have access to comprehensive epidemiological surveillance research tools, said Robert Lipshutz, Ph.D., senior vice president, corporate development and emerging markets at Affymetrix. We are pleased to have Tessare join our Powered by Affymetrix program and we anticipate that the availability of these types of microarray-based testing kits and services will allow epidemiologists to better monitor the spread of pathogens and detect mutations that may alter their potential to cause a pandemic.






Related Links:
Affymetrix
Tessare

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Immunofluorescence Analyzer
IFA System
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.